Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Mecbotamab Vedotin · BA-3011

Antibody-drug conjugate · Cytotoxic, directed at AXL receptor tyrosine kinase (AXL) · developed by BioAtla

Phase 2 Most advanced trial
1 Registered trials

What is Mecbotamab Vedotin?

Mecbotamab vedotin is an antibody-drug conjugate built from a conditionally active antibody against the AXL receptor tyrosine kinase, linked to a cytotoxic agent. The antibody binds AXL-expressing tumor cells preferentially under tumor microenvironment conditions, and after internalization the payload kills the cells. It is being studied in ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BA-3011
Drug type
Antibody-drug conjugate
Targets
AXL receptor tyrosine kinase (AXL)
Mechanism
Cytotoxic, directed at AXL receptor tyrosine kinase (AXL)
Therapy area
Oncology
Developer
BioAtla, Inc.
In trials of
AZN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
VF40YVX65F

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04918186 Phase 2 Ovarian Cancer Recruiting AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian Cancer

Other drugs acting on AXL

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.